

The Centers for Medicare & Medicaid Services' Office of Research, Development, and Information (ORDI) strives to make information available to all. Nevertheless, portions of our files including charts, tables, and graphics may be difficult to read using assistive technology.

Persons with disabilities experiencing problems accessing portions of any file should contact ORDI through e-mail at ORDI_508_Compliance@cms.hhs.gov.

**STATISTICAL COMPENDIUM:
MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT IN 2005
MARYLAND**

LIST OF TABLES

OVERVIEW OF STUDY POPULATION

TABLE 1. OVERVIEW OF BENEFICIARY SELECTION CRITERIA FOR STUDY POPULATION

FOR ALL MEDICAID BENEFICIARIES

TABLE 2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE 3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE 4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE 5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE 6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE 7. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

FOR ALL NONDUAL BENEFICIARIES

TABLE ND.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE ND.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE ND.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE ND.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND

BENEFICIARY CHARACTERISTIC

TABLE ND.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE ND.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

TABLE ND.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC

TABLE ND.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND

THERAPEUTIC CATEGORY

TABLE ND.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS,

BY TOP 10 DRUG GROUP

TABLE ND.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS, BY

BENEFICIARY CHARACTERISTIC

TABLE ND.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS PER BENEFIT MONTH,

BY BENEFICIARY CHARACTERISTIC

TABLE ND.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES

AMONG NONDUALS

FOR DUAL ELIGIBLE BENEFICIARIES

TABLE D.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE D.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE D.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE D.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND

BENEFICIARY CHARACTERISTIC

TABLE D.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE D.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

TABLE D.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC

TABLE D.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND

THERAPEUTIC CATEGORY

TABLE D.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS,

BY TOP 10 DRUG GROUP

TABLE D.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS, BY BENEFICIARY CHARACTERISTIC

TABLE D.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS PER BENEFIT MONTH, BY

BENEFICIARY CHARACTERISTIC

TABLE D.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG DUALS

SUPPLEMENTAL TABLES

SUPPLEMENTAL TABLE 1. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES

SUPPLEMENTAL TABLE 1A. MEDICAID PHARMACY REIMBURSEMENT FOR DISABLED DUAL ELIGIBLE BENEFICIARIES UNDER AGE 65

SUPPLEMENTAL TABLE 1B. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 AND OLDER

SUPPLEMENTAL TABLE 1C. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 TO 74

SUPPLEMENTAL TABLE 1D. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 75 TO 84

SUPPLEMENTAL TABLE 1E. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 85 AND OLDER

APPENDIX TABLES

APPENDIX TABLE A.1. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, NONDUAL BENEFICIARIES

APPENDIX TABLE A.2. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, NONDUAL BENEFICIARIES
APPENDIX TABLE A.3. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, DUAL ELIGIBLE BENEFICIARIES
APPENDIX TABLE A.4. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, DUAL ELIGIBLE BENEFICIARIES

TABLE 1
OVERVIEW OF BENEFICIARY SELECTION CRITERIA FOR STUDY POPULATION
MARYLAND, 2005

Inclusion Criteria (2005)	Number of Dual and Non-dual Eligible Beneficiaries (Cell)	Number of Dual Eligible Beneficiaries (Cell) ^g	Number of Non-dual Eligible Beneficiaries (Cell)
1. Beneficiaries who were eligible for Medicaid during at least one month ^a	859101 (A)	119708 (E)	739393 (I)
2. Beneficiaries who had Medicaid pharmacy benefits during at least one month ^b	847149 (B)	115595 (F)	731554 (J)
3. Beneficiaries who had fee-for-service pharmacy benefit coverage during at least one month ^{c, d, e}	404981 (C)	112662 (G)	292319 (K)
4. Beneficiaries who were all-year nursing facility residents ^f	15969 (D)	14090 (H)	1879 (L)

Source: Data for this table are from the MAX 2005 file for Maryland, released by CMS in 1/2009. This table was produced on 04/23/2009.

a. MAX data element "Eligible Months Count" was used to determine an individual's Medicaid eligibility. All individuals who had a value greater than zero were considered as beneficiaries and counted in Cell A.

b. Counts in Cell B were obtained by excluding from Cell A beneficiaries who never had pharmacy benefit coverage during their Medicaid enrollment in 2005 (based on MAX data element "Eligible Restricted Benefits Flag").

c. Cell C represents the study population for Tables 2 through 7. Cell C was obtained by excluding from Cell B beneficiaries who were in managed care (MC) plans that included prescription drugs in their capitated benefit package during all months of Medicaid eligibility in 2005, because the MAX files do not include separate prescription drug claims for those beneficiaries. MC plans include health maintenance organizations (HMOs), prepaid health plans (PHPs), or other MC organizations that provide health care benefits under capitation arrangements. Beneficiaries included in the study population are those who were in fee-for-service or primary care case management (PCCM) programs. In addition, beneficiaries in selected states in which prescription drug benefits were not covered in the capitated benefit package in MC or PHP plans are also included (see footnote e for a list of these states). In those states, if a beneficiary spent part of the year in fee-for-service, PCCM, or in a PHP or MC plan in which drugs were not included in the capitation, and spent part of the year in a PHP or MC plan in which drugs were capitated, only the months with fee-for-service pharmacy benefits are included in the tables. For example, if a beneficiary was in an MC plan that did not include prescription drugs in the capitation for 3 months of the year, and in a PHP with capitated drug coverage for the remaining 9 months, only the 3 months would be counted toward the number of benefit months associated with the beneficiary. Therefore, benefit months included represent the benefit months with fee-for-service pharmacy benefits.

d. The total Medicaid pharmacy reimbursement for Maryland in 2005 was \$464,618,391, of which \$106,746,362 was excluded from our analysis because those claims were made for beneficiaries who were outside the study population or took place during months that were excluded from the analysis.

e. Enrollees in prepaid health plans (PHP) or managed care (MC) plans that did not provide a pharmacy benefit are treated as having fee-for-service pharmacy benefit coverage. There were 26 states in 2005 that had PHPs that did not include a pharmacy benefit: AL, AR, AZ, CA, CO, FL, GA, IA, KY, MA, MI, MS, NH, NV, NY, OH, OK, OR, PA, SC, SD, TN, TX, UT, WA, and WI. In addition, there were 8 states in which MC plans did not provide a pharmacy benefit (DE, IA, IL, NE, NY, TX, UT, and WV) and one state (NV) in which MC plans provided a pharmacy benefit for non-duals but not for duals. These lists were constructed from the CMS 2005 Medicaid Managed Care Enrollment Report <http://www.cms.hhs.gov/MedicaidDataSourcesGenInfo/Downloads/mmcer05.pdf> and by checking PHP and MC pharmacy coverage as necessary through state, PHP, and MC web sites. As a further check, we analyzed prescription drug claims for those reported as being in managed care all year in the MAX files (see Appendix Tables A.1 and A.3) to determine whether the annual number and cost of claims per person for those beneficiaries were comparable to those of beneficiaries reported as being in fee-for-service all year. If they were, that provided additional evidence that prescription drugs were not included in the managed care capitated benefit package.

f. Cell H represents the study population for Tables D.8 through D.10D. Cell L represents the study population for Tables ND.8 through ND.10D. All-year nursing facility residents are the beneficiaries who resided in nursing facilities throughout their enrollment in 2005. These beneficiaries were identified by comparing the number of months during which the MAX files contained at least one claim from nursing facilities to the number of Medicaid eligible months. If the former is greater than or equal to the latter, the beneficiary was considered an all-year resident. If the former is less than the latter but not equal to zero, the beneficiary was considered a part-year resident. Part-year residents are treated separately because they are likely to be short-term residents and the level and pattern of their pharmacy benefit use may differ substantially from longer-term residents. The number of part-year residents and their benefit months are presented in footnotes to Tables D.8 through D.10D and N+B18D.8 through ND.10D. Residents of mental hospitals for the aged, inpatient psychiatric facilities for individuals under age 21, or intermediate care facilities for the mentally retarded are not counted as nursing facility residents in the nursing facility tables.

g. Pharmacy benefit use and reimbursement among full dual eligible beneficiaries are presented in Tables D.2 through D.7D, Tables D.11 through D.13, and Supplemental Tables 1 through 1E corresponding to the sample of beneficiaries in Cell G. To determine Medicaid-Medicare dual eligibility status, two MAX data elements ("Eligible Medicare Crossover Code -- Annual New Values" and "Eligible Restricted Benefits Flag") were used in combination. The dual eligible tables include all dual eligible benefit months in which the beneficiary had a fee-for-service pharmacy benefit.

Beneficiaries represented in Cell G, the dual study population, include all dual eligible beneficiaries who had a fee-for-service pharmacy benefit at least during one month in 2005. The dual eligible tables include all dual eligible benefit months in which the beneficiary had a fee-for-service pharmacy benefit.

Characteristics of non-dual eligible beneficiaries represented by Cell J are shown in Appendix Table A.1 and characteristics of non-dual eligible beneficiaries and their benefit months included in Cell J but excluded from Cell K are shown in Appendix Table A.2. Characteristics of dual eligible beneficiaries represented by Cell F are shown in Appendix Table A.3, and characteristics of dual eligible beneficiaries and their benefit months included in Cell F but excluded from Cell G are shown in Appendix Table A.4.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; HMO = health maintenance organization; MAX = Medicaid Analytic Extract; MC = managed care; PCCM = primary care case management; PHP = prepaid health plan.

TABLE 2
CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY^{a, b}
MARYLAND, 2005

Beneficiary Characteristics	Number of Beneficiaries						Number of Benefit Months					
	All	Aged	Disabled	Adults	Children	Other/ Unknown	All	Aged	Disabled	Adults	Children	Other/ Unknown
All	404,981	66,045	74,607	138,694	125,212	423	2,675,596	681,273	673,943	1,033,881	282,379	4,120
Age												
5 and younger	50,475	1	752	1	49,721	0	95,945	12	3,552	1	92,380	0
6-14	48,315	5	1,205	19	47,086	0	97,484	37	6,445	47	90,955	0
15-20	32,895	2	1,760	3,372	27,761	0	114,728	13	9,972	7,839	96,904	0
21-44	137,094	43	23,230	113,146	633	42	1,059,684	471	202,201	854,557	2,089	366
45-64	58,116	205	35,490	22,054	0	367	494,526	2,110	317,986	170,778	0	3,652
65-74	31,567	23,974	7,498	81	0	14	333,224	250,306	82,301	515	0	102
75-84	29,175	25,743	3,415	17	0	0	309,512	270,937	38,458	117	0	0
85 and older	17,333	16,072	1,257	4	0	0	170,442	157,387	13,028	27	0	0
Unknown	11	0	0	0	11	0	51	0	0	0	51	0
Gender												
Female	268,138	48,751	38,631	114,553	65,780	423	1,900,904	509,001	359,965	866,128	161,690	4,120
Male	136,843	17,294	35,976	24,141	59,432	0	774,692	172,272	313,978	167,753	120,689	0
Unknown	0	0	0	0	0	0	0	0	0	0	0	0
Race												
White	148,997	30,487	33,204	53,242	31,830	234	1,116,331	310,135	311,207	415,080	77,643	2,266
African American	196,967	23,958	35,068	71,300	66,521	120	1,217,390	250,250	309,296	505,459	151,201	1,184
Other/unknown	59,017	11,600	6,335	14,152	26,861	69	341,875	120,888	53,440	113,342	53,535	670
Use of Nursing Facilities^c												
Entire year	15,969	13,052	2,912	3	2	0	157,459	127,068	30,352	15	24	0
Part year	8,120	5,406	2,658	49	5	2	72,573	48,333	23,785	403	35	17
None	380,892	47,587	69,037	138,642	125,205	421	2,445,564	505,872	619,806	1,033,463	282,320	4,103
Maintenance Assistance Status												
Cash	90,686	19,188	39,526	15,085	16,887	0	676,242	216,046	380,152	43,148	36,896	0
Medically needy	57,948	21,213	17,444	10,368	8,923	0	360,001	192,674	107,245	33,834	26,248	0
Poverty-related	105,168	405	544	14,691	89,105	423	222,031	4,110	5,035	48,127	160,639	4,120
Other/unknown	151,179	25,239	17,093	98,550	10,297	0	1,417,322	268,443	181,511	908,772	58,596	0
Dual Medicare Status^d												
Full dual, all year	110,738	59,801	46,459	4,435	24	19	1,163,658	618,225	500,479	44,597	181	176
Full dual, part year	1,924	1,021	878	25	0	0	20,002	10,898	8,833	271	0	0
Non-dual, all year	292,319	5,223	27,270	134,234	125,188	404	1,491,936	52,150	164,631	989,013	282,198	3,944
Managed Care (MC) Status												
Fee-for-service (FFS) all year	233,082	65,558	57,751	93,566	15,786	421	2,206,373	678,243	597,111	857,119	69,794	4,106
FFS part year, with Rx claims	45,490	431	11,226	17,169	16,662	2	165,981	2,754	52,596	71,857	38,760	14
FFS part year, no Rx claims	126,409	56	5,630	27,959	92,764	0	303,242	276	24,236	104,905	173,825	0

Source: Data for this table are from the MAX 2005 file for Maryland, released by CMS in 1/2009. This table was produced on 04/23/2009.

a. Table 2 includes the beneficiaries represented by Cell C of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

d. The "Full dual, all year" group includes beneficiaries who had Medicare coverage as well as Medicaid fee-for-service pharmacy benefits during all months of Medicaid enrollment in 2005. The "Full dual, part year" group includes beneficiaries who had such benefits for some, but not all, months of their enrollment. The "Non-dual, all year" group includes beneficiaries who were never dually eligible. Refer to footnote g of Table 1 for more information about how we determined dual eligibility status.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

All Medicaid Beneficiaries

TABLE 3
ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC^{a, b}
MARYLAND, 2005

Beneficiary Characteristics	Percentage with at Least One Rx	Mean Number of Rx	Mean Rx \$	\$ per Rx	Mean \$, All Medicaid FFS \$ ^c	Rx \$ as a Percentage of All Medicaid FFS \$ ^d	Number of Beneficiaries
All	38.5	13.7	\$884	\$64	\$7,712	11.5	404,981
Age							
5 and younger	12.1	0.3	20	63	2,890	0.7	50,475
6-14	14.6	1.2	126	107	2,431	5.2	48,315
15-20	23.9	2.3	223	99	5,496	4.1	32,895
21-44	29.7	5.2	476	91	5,235	9.1	137,094
45-64	52.4	24.1	1,771	73	12,984	13.6	58,116
65-74	78.6	38.5	2,196	57	10,550	20.8	31,567
75-84	82.2	43.8	2,333	53	15,317	15.2	29,175
85 and older	86.3	46.5	2,188	47	24,626	8.9	17,333
Unknown	9.1	0.1	1	8	1,001	0.1	11
Basis of Eligibility^e							
Aged	80.4	40.8	2,113	52	15,493	13.6	66,045
Disabled	74.6	34.7	2,656	76	19,345	13.7	74,607
Adults	20.2	1.1	65	59	2,265	2.9	138,694
Children	15.0	0.9	83	91	2,698	3.1	125,212
Unknown	85.1	25.2	1,902	76	10,983	17.3	423
Gender							
Female	39.8	14.1	846	60	7,093	11.9	268,138
Male	36.0	13.0	958	74	8,924	10.7	136,843
Unknown	0.0	0.0	0	0	0	0.0	0
Race							
White	47.9	19.8	1,246	63	10,017	12.4	148,997
African American	33.1	10.3	687	67	6,631	10.4	196,967
Other/unknown	32.7	9.8	624	64	5,501	11.4	59,017
Use of Nursing Facilities^f							
Entire year	97.0	78.7	4,030	51	52,246	7.7	15,969
Part year	94.9	60.8	3,337	55	37,722	8.8	8,120
None	34.8	10.0	700	70	5,205	13.4	380,892
Maintenance Assistance Status							
Cash	60.7	25.7	1,849	72	11,536	16.0	90,686
Medically needy	59.9	29.9	1,631	55	23,489	6.9	57,948
Poverty related	16.1	0.7	51	74	2,279	2.2	105,168
Other/unknown	32.6	9.4	598	64	3,150	19.0	151,179

Source: Data for this table are from the MAX 2005 file for Maryland, released by CMS in 1/2009. This table was produced on 04/23/2009.

a. Table 3 includes beneficiaries represented by Cell C of Table 1.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.

d. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.

e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability

or blindness. The children's group includes children receiving foster care and adoptive services.

f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

All Medicaid Beneficiaries

TABLE 4
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC^{a, b}
 MARYLAND, 2005

Beneficiary Characteristics	Mean Number of Rx	Mean Rx \$	Rx \$ as a Percentage of All Medicaid FFS \$ ^c	Number of Rx, Percentage with:						Mean \$, All Medicaid FFS \$ ^d	Number	
				None	More than 0, but 1 or Less	More than 1, but 2 or Less	More than 2, but 5 or Less	More than 5, but 10 or Less	More than 10		Beneficiaries	Benefit Months
All	2.1	\$134	11.5	61.5	14.2	4.8	9.4	7.1	2.9	\$1,167	404,981	2,675,596
Age												
5 and younger	0.2	10	0.7	87.9	8.9	2.0	1.0	0.2	0.1	1,520	50,475	95,945
6-14	0.6	63	5.2	85.4	6.8	2.3	2.7	1.7	1.2	1,205	48,315	97,484
15-20	0.6	64	4.1	76.1	15.1	2.9	3.3	1.6	1.1	1,576	32,895	114,728
21-44	0.7	62	9.1	70.3	18.3	3.2	4.5	2.5	1.2	677	137,094	1,059,684
45-64	2.8	208	13.6	47.6	13.5	6.9	14.5	12.0	5.5	1,526	58,116	494,526
65-74	3.7	208	20.8	21.4	17.9	11.1	25.2	18.3	5.9	999	31,567	333,224
75-84	4.1	220	15.2	17.8	14.6	10.5	27.2	22.1	7.7	1,444	29,175	309,512
85 and older	4.7	223	8.9	13.7	11.3	9.9	28.4	27.4	9.3	2,504	17,333	170,442
Unknown	0.0	0	0.1	90.9	9.1	0.0	0.0	0.0	0.0	216	11	51
Basis of Eligibility^e												
Aged	4.0	205	13.6	19.6	15.6	10.6	26.0	21.0	7.3	1,502	66,045	681,273
Disabled	3.8	294	13.7	25.4	18.6	9.7	21.6	17.3	7.4	2,142	74,607	673,943
Adults	0.1	9	2.9	79.8	15.7	1.9	1.7	0.6	0.3	304	138,694	1,033,881
Children	0.4	37	3.1	85.0	9.2	2.2	2.0	1.0	0.6	1,197	125,212	282,379
Unknown	2.6	195	17.3	14.9	29.1	18.2	27.9	9.2	0.7	1,128	423	4,120
Gender												
Female	2.0	119	11.9	60.2	15.5	4.8	9.5	7.2	2.8	1,001	268,138	1,900,904
Male	2.3	169	10.7	64.0	11.8	5.0	9.4	6.9	2.9	1,576	136,843	774,692
Unknown	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0	0
Race												
White	2.6	166	12.4	52.1	15.1	5.4	12.1	10.6	4.7	1,337	148,997	1,116,331
African American	1.7	111	10.4	66.9	13.8	4.5	7.7	5.3	1.9	1,073	196,967	1,217,390
Other/unknown	1.7	108	11.4	67.3	13.5	4.8	8.5	4.5	1.4	950	59,017	341,875
Use of Nursing Facilities^f												
Entire year	8.0	409	7.7	3.0	3.4	4.4	23.8	40.2	25.3	5,299	15,969	157,459
Part year	6.8	373	8.8	5.1	7.3	7.6	26.4	35.0	18.7	4,221	8,120	72,573
None	1.6	109	13.4	65.2	14.8	4.8	8.5	5.1	1.6	811	380,892	2,445,564
Maintenance Assistance Status												
Cash	3.5	248	16.0	39.3	16.4	8.5	18.2	12.8	4.7	1,547	90,686	676,242
Medically needy	4.8	263	6.9	40.1	12.8	6.0	14.8	16.9	9.3	3,781	57,948	360,001
Poverty related	0.3	24	2.2	83.9	10.5	2.5	2.0	0.7	0.4	1,079	105,168	222,031
Other/unknown	1.0	64	19.0	67.4	16.1	3.8	7.3	4.4	0.9	336	151,179	1,417,322

Source: Data for this table are from the MAX 2005 file for Maryland, released by CMS in 1/2009. This table was produced on 04/23/2009.

a. Table 4 includes the beneficiaries represented by Cell C of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.

d. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.

e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

All Medicaid Beneficiaries

TABLE 5
 AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC^{a, b, c}
 MARYLAND, 2005

Beneficiary Characteristics	All Rx			Patented Brand-Name Drugs			Off-Patent Brand-Name Drugs			Generic Drugs		
	Number of Rx	Rx \$	\$ per Rx	Number of Rx	Rx \$	\$ per Rx	Number of Rx	Rx \$	\$ per Rx	Number of Rx	Rx \$	\$ per Rx
All	2.1	\$134	\$64	0.9	\$108	\$125	0.1	\$5	\$65	1.1	\$21	\$18
Age												
5 and younger	0.2	10	63	0.0	9	182	0.0	0	80	0.1	2	14
6-14	0.6	63	107	0.4	57	152	0.0	1	109	0.2	4	21
15-20	0.6	64	99	0.4	57	153	0.0	2	81	0.3	6	22
21-44	0.7	62	91	0.3	50	177	0.0	3	101	0.4	9	25
45-64	2.8	208	73	1.1	165	148	0.1	9	82	1.6	34	21
65-74	3.7	208	57	1.5	169	109	0.1	7	58	2.0	32	16
75-84	4.1	220	53	1.8	179	100	0.2	9	49	2.2	33	15
85 and older	4.7	223	47	1.8	174	94	0.3	11	45	2.6	37	14
Unknown	0.0	0	8	0.0	0	0	0.0	0	0	0.0	0	8
Basis of Eligibility^d												
Aged	4.0	205	52	1.6	164	100	0.2	9	49	2.1	32	15
Disabled	3.8	294	76	1.6	237	151	0.1	12	83	2.1	45	21
Adults	0.1	9	59	0.1	6	103	0.0	0	74	0.1	2	24
Children	0.4	37	91	0.2	33	142	0.0	1	80	0.2	3	19
Unknown	2.6	195	76	1.0	166	164	0.1	6	81	1.5	24	16
Gender												
Female	2.0	119	60	0.8	95	116	0.1	5	64	1.1	19	18
Male	2.3	169	74	1.0	139	143	0.1	6	68	1.2	24	20
Unknown	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0
Race												
White	2.6	166	63	1.1	132	122	0.1	8	65	1.4	27	19
African American	1.7	111	67	0.7	91	133	0.1	4	66	0.9	16	18
Other/unknown	1.7	108	64	0.8	90	114	0.1	4	59	0.9	15	17
Use of Nursing Facilities^e												
Entire year	8.0	409	51	3.0	314	105	0.5	24	48	4.5	70	16
Part year	6.8	373	55	2.5	289	115	0.4	21	53	3.9	63	16
None	1.6	109	70	0.7	89	132	0.0	4	81	0.8	16	19
Maintenance Assistance Status												
Cash	3.5	248	72	1.5	204	135	0.1	8	75	1.8	36	20
Medically needy	4.8	263	55	1.9	205	110	0.3	14	51	2.7	43	16
Poverty related	0.3	24	74	0.1	21	138	0.0	1	77	0.2	3	17
Other/unknown	1.0	64	64	0.4	51	123	0.0	3	80	0.6	10	18

Source: Data for this table are from the MAX 2005 file for Maryland, released by CMS in 1/2009. This table was produced on 04/23/2009.

a. Table 5 includes the beneficiaries represented by Cell C of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies

other than the original patent holder. In Maryland, 0.1 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions

combined. For information about this classification method, see Wolters Kluwer Health, <http://www.medispn.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007)

d. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

e. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

All Medicaid Beneficiaries

TABLE 6
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY^{a, b, c, d}
 MARYLAND, 2005

Therapeutic Category	Number of Rx per Benefit Month Among Users			\$ per Benefit Month Among Users									\$ per Rx		Users ^e		
	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total Number of Rx	Total Rx \$	Number of Users	As a Percentage of All Benes	Number of Benefit Months
Anti-infective Agents	0.4	0.1	0.0	0.2	\$45	\$37	\$3	\$4	\$117	\$301	\$86	\$19	258,328	\$30,214,255	69,519	17.2	678,414
Biologicals	0.2	0.1	0.0	0.1	87	63	3	20	569	769	3,815	296	809	460,393	553	0.1	5,322
Antineoplastic Agents	0.5	0.2	0.0	0.3	110	87	1	22	217	518	306	65	22,131	4,798,089	4,368	1.1	43,686
Endocrine/Metabolic Drugs	0.8	0.3	0.1	0.4	39	30	3	6	47	91	42	15	564,881	26,614,176	66,015	16.3	675,215
Cardiovascular Agents	1.6	0.7	0.0	0.9	67	54	0	12	40	78	18	13	1,406,737	56,865,847	81,501	20.1	852,875
Respiratory Agents	0.7	0.3	0.0	0.3	37	33	1	3	56	95	62	11	311,580	17,343,083	47,153	11.6	463,932
Gastrointestinal Agents	0.8	0.4	0.0	0.3	60	56	0	4	79	127	49	12	400,204	31,781,324	50,631	12.5	529,418
Genitourinary Agents	0.5	0.3	0.0	0.2	29	25	1	3	59	78	61	20	91,304	5,395,007	18,042	4.5	185,250
CNS Drugs	1.4	0.7	0.0	0.7	122	108	1	13	88	156	71	19	911,251	80,523,065	72,449	17.9	660,589
Stimulants/Anti-obesity/Anorexia	1.2	0.9	0.0	0.3	121	110	1	9	100	122	218	31	38,827	3,871,147	6,490	1.6	32,059
Miscellaneous Psychological/Neurological Agents	0.8	0.8	0.0	0.0	121	119	0	2	154	155	106	100	67,735	10,406,338	8,318	2.1	85,774
Analgesics and Anesthetics	0.7	0.1	0.1	0.6	36	12	9	15	51	152	164	26	438,385	22,501,293	62,688	15.5	624,799
Neuromuscular Agents	1.0	0.3	0.1	0.6	71	46	4	21	69	140	51	34	390,327	27,026,327	38,320	9.5	380,571
Nutritional Products	0.5	0.0	0.0	0.5	7	0	0	6	12	38	15	12	147,121	1,813,655	28,846	7.1	272,789
Hematological Agents	0.8	0.4	0.1	0.4	81	74	2	5	98	210	18	13	229,084	22,460,452	26,782	6.6	277,210
Topical Products	0.5	0.2	0.0	0.3	24	18	1	5	49	84	52	19	266,840	13,097,703	52,718	13.0	539,053
Miscellaneous Products	0.4	0.1	0.0	0.2	65	52	3	10	182	405	311	44	14,460	2,630,944	3,915	1.0	40,266
Unknown Therapeutic Category	0.3	0.0	0.0	0.0	5	0	0	0	16	0	0	0	4,443	68,931	1,361	0.3	14,604
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	5,564,447	357,872,029	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2005 file for Maryland, released by CMS in 1/2009. This table was produced on 04/23/2009.

a. Table 6 includes the beneficiaries represented by Cell C of Table 1. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. For information about these therapeutic categories, see Wolters Kluwer Health, <http://www.medspan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

d. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than

the original patent holder. In Maryland, 0.1 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined.

For information about this classification method, see Wolters Kluwer Health, <http://www.medspan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

e. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2005.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE 7
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP^{a, b, c}
 MARYLAND, 2005

Top 10 Drug Groups	Users			Among Users			
	Total Medicaid Rx \$	Number	As a Percentage of All Beneficiaries	Number of Benefit Months	Number of Rx per Benefit Month	\$ per Rx	Rx \$ per Benefit Month
ANTIPSYCHOTICS	\$49,743,868	34,055	8.4	362,099	0.8	\$172	\$137
ULCER DRUGS	26,378,262	46,762	11.5	500,949	0.6	92	53
ANTIHYPERLIPIDEMIC	24,374,626	42,280	10.4	472,468	0.6	90	52
ANTICONVULSANT	22,619,890	30,885	7.6	329,087	0.8	84	69
ANTIVIRAL	19,496,239	10,247	2.5	106,683	0.4	444	183
ANTIDEPRESSANTS	16,816,381	48,806	12.1	513,169	0.7	50	33
ANTIDIABETIC	16,579,530	45,097	11.1	487,806	0.6	53	34
ANALGESICS - Narcotic	14,191,195	64,400	15.9	671,087	0.4	50	21
ANTIASTHMATIC	12,860,695	45,035	11.1	465,237	0.4	63	28
ANTIHYPERTENSIVE	12,400,369	59,634	14.7	646,008	0.6	34	19
Total	215,461,055	427,201		4,554,593	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2005 file for Maryland, released by CMS in 1/2009. This table was produced on 04/23/2009.

a. Table 7 includes the beneficiaries represented by Cell C of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispn.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

All Medicaid Beneficiaries